Vera Therapeutics, Inc. Class A (VERA)

Several key events have influenced Vera Therapeutics' stock price over the past six months. The FDA accepted the BLA for atacicept and granted it Priority Review, coinciding with a stock gain. A December 2025 equity offering resulted in a modest negative reaction. The company participated in the J.P. Morgan Healthcare Conference in January 2026. Inducement grants and leadership changes have led to mixed stock movements. Promising Phase 3 data for atacicept led to a rally, but enthusiasm was tempered by a rival therapy. The stock experienced a 122.39% increase over the past six months, but a -14.28% change year-to-date as of February 8, 2026.

As a clinical-stage biotechnology company, Vera Therapeutics is currently pre-revenue from product sales. Its financial performance is primarily tied to achieving clinical and regulatory milestones rather than traditional product demand seasonality. The company anticipates a potential U.S. commercial launch of atacicept in July 2026, at which point market dynamics and potential seasonality for a specialized pharmaceutical product would begin to emerge.

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. Their primary product candidate is atacicept, a fusion protein in Phase 3 development for IgA nephropathy and Phase 2 trials for other autoimmune kidney diseases. They are also developing MAU868, a monoclonal antibody for BK virus infection, and VT-109, a preclinical asset for immune modulation.

Vera Therapeutics is headquartered in Brisbane, California, and was founded in San Francisco in 2016. The company retains global rights to atacicept and MAU868.

Vera Therapeutics maintains a generally positive brand reputation, driven by the potential of atacicept. Positive Phase 3 results from the ORIGIN 3 trial validated the drug's mechanism. Wall Street analysts have a generally positive outlook on VERA. Atacicept has been granted FDA Breakthrough Therapy Designation for IgAN. The company's leadership is focused on clinical translation and advancing novel therapies.

Vera Therapeutics has a significant institutional ownership base. As of the fourth quarter of 2025, 414 institutions held shares, accounting for approximately 103.78% of the total shares. Institutional investors collectively hold 98.59% of the shares, while individuals hold 1.06%. Company insiders hold 33.46% of the ownership.